drugset / Trial / NCT06113744
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
Phase 1
Unknown
164 enrolled
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A randomised, blinded, parallel-controlled phase 1 clinical trial to evaluate the safety and preliminary immunogenicity of a COVID-19 mRNA vaccine in a healthy population aged 18 years and older, and to investigate immunisation doses.
Timeline
- Start
- 2023-03-10
- Primary completion
- 2023-06-30
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | — | — |
| Subject | ZSVG-02-O | Messenger RNA (mRNA) | 10 ug | — |
| Subject | ZSVG-02-O | Messenger RNA (mRNA) | 30 ug | — |
| Subject | ZSVG-02-O | Messenger RNA (mRNA) | 60 ug | — |